Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Turns Up Heat On Bid To Acquire CV Therapeutics

This article was originally published in PharmAsia News

Executive Summary

Following CV Therapeutics' refusal to accept its $16 per share purchase bid, Astellas is trying to turn up the pressure on CVT with a two-pronged approach involving both a tender offer for outstanding shares and a lawsuit in Delaware Chancery Court

You may also be interested in...



CV Therapeutics Again Declines Astellas $16 Per Share Purchase Offer

Less than a month after Astellas made public its bid to purchase CV Therapeutics for $16 a share for a total price of nearly $1 billion, CVT turned down the offer Feb. 20 as "significantly undervaluing" the biotech and not serving the best interests of the company or its stockholders

Astellas Looks To Increase U.S. Presence With Bid For CV Therapeutics

In a surprise move spurred by a desire to own a greater share of the promising angina drug Ranexa, Astellas announced Jan. 27 its hostile offer for partner CV Therapeutics in a cash deal worth roughly $1 billion

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel